Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Tencent Holdings | SK Hynix | Moderna | |
|---|---|---|---|
| Moat rating | wide The 2025 Annual Report reports combined MAU of Weixin and WeChat of 1,418 million at 31 December 2025, still growing 2% year-on-year and 0.3% quarter-on-quarter off a 1.4-billion-account base, while group gross margin rose to 56% from 53% and Marketing Services revenue grew 19% to RMB145.0 billion 'primarily driven by growth in pricing and ad impressions'. Rising price on a still-growing user base of that size is the signature of a wide moat, not a contested one. | narrow SK hynix held ~62% of the AI-critical HBM market in Q2 2025 (Counterpoint, via TweakTown) and was first to mass-produce HBM4, but memory remains a cyclical three-player business where Samsung and Micron are closing the HBM gap — a real but contestable edge. | narrow The FY2025 10-K supports a real but bounded advantage. The Competition section says the company believes "mRNA as a medicine coupled with our capabilities across mRNA technology, drug discovery, development and manufacturing provide us with a competitive advantage," and the Intellectual Property section backs that with more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed outside the U.S., 485 pending applications, and latest-to-expire granted patents on all three approved products projected to 2041 in the U.S. and 2036 in Europe. Item 1A cuts the band down from wide: it opens the competition risk with "The vaccine market, and pharmaceutical market more generally, is intensely competitive," says Moderna "ha[s] been excluded from selling our COVID vaccines in many European markets due to a competitor's contract with the European Commission, which does not lapse until year-end 2026," that in RSV it "entered a market already occupied by two larger competitors," and that rivals "have exploited and may in the future exploit their greater size, infrastructure, resources and experience." The same section reports net losses of $2.8 billion in 2025 and $3.6 billion in 2024 against 2025 total revenue of $1.9 billion. |
| Moat type | network effects The report attributes Marketing Services pricing growth to 'an increasing proportion of closed-loop ads (where the user clicks through to native transactional experiences, such as Mini Programs, Mini Shops, or Mini Games)' and describes growing engagement with Mini Shops, Mini Games and content Mini Programs 'by strengthening Weixin's commerce experience and content ecosystem' - merchants and developers building inside the user graph rather than beside it, which is a network effect rather than a switching cost or a scale cost advantage. | intangibles ip The advantage is process-and-packaging technology leadership: SK hynix achieved industry-first HBM4 mass production in September 2025 and has positioned itself as NVIDIA's key HBM partner, per its record FY2025 results. | intangibles ip The filing locates the advantage in a patent and know-how estate, not in customer lock-in or cost. Intellectual Property describes "an expansive, multi-layered IP estate" whose platform claims cover mRNA chemistry, sequence optimization, engineering elements, LNP delivery systems and "innovative processes for the manufacture and analysis of mRNA drug substance and formulated drug product," alongside "substantial proprietary know-how associated with related manufacturing processes" and a trademark portfolio of at least 1,400 registrations. Nothing in the filing claims switching costs or a cost advantage; Item 1A says the opposite, that competitors leverage "larger supply chains and greater purchasing power." |
| Leadership | clear leader The only explicit leadership claims in the report are the Company's own: Tencent Video 'maintained its leading position in China's long-form video market' and Tencent Music 'extended its leading position in China's music streaming market'. Against a 1,418 million combined Weixin/WeChat MAU base, the report asserts leadership in the adjacent content markets and no competitor is named anywhere in it. | clear leader Clear leader in HBM (#1 at ~62% share, Q2 2025) and became the world's top overall memory supplier in Q2 2025; caveat: it sits #2 to Samsung in commodity DRAM by volume and Micron/Samsung are narrowing the HBM gap heading into HBM4. | co leader The Business section opens with the company's own claim that "Moderna is a pioneer and leader in the field of mRNA medicine." The Competition section frames the commercial reality more narrowly as a contest against a small named set: "We largely compete against Pfizer and BioNTech for sales of our COVID vaccines, whose vaccine is also based on mRNA technology. We also compete against other vaccines, including Sanofi and Novavax's." It does not claim a rank anywhere, and it places Moderna behind in the other approved category: in RSV "we compete against Pfizer and GlaxoSmithKline, who entered the U.S. market prior to us, and our RSV sales have been minimal to date." |
| Pricing power | strong Group gross margin was 56% for 2025, up from 53%, with segment gross margins of 60% for VAS (from 57%), 58% for Marketing Services (from 55%) and 51% for FinTech and Business Services (from 47%); Marketing Services revenue growth is attributed 'primarily' to pricing, and the Chairman's Statement notes ad load 'remained at a much lower level than peers'' - price is rising with monetisation headroom still unused. | strong FY2025 operating margin hit a record 49% (operating profit +101% YoY) as HBM revenue more than doubled — unusually strong pricing power for a memory maker, per SK hynix's FY25 release. | weak Item 1A states that "certain U.S. private vaccine market practices, including regarding discounts, rebates and returns, may cause us to realize significantly lower revenues than list prices," and that "in some instances, our competitors have been able to offer more attractive terms than we can, and they may continue to do so in the future." On the flu candidate it says that in a well-developed market Moderna "may need to offer more favorable terms to gain market share (which we may be unable to do), which may negatively impact our profitability." The Commercial section adds that its markets are "characterized, particularly in the U.S. (our largest market), by a fragmented end customer base, unpredictability in orders and seasonality of deliveries." |
| Summary | The textbook answer holds, but not for the textbook reason. Weixin's value is that third parties transact inside it: the report ties Marketing Services growth to closed-loop ads landing in Mini Programs, Mini Shops and Mini Games, ties Business Services growth to 'higher eCommerce technology service fees, underpinned by growth in Mini Shops GMV', and reports that ad load 'remained at a much lower level than peers', so the graph is being monetised deliberately below capacity. On gaming regulation the record is thinner than the received narrative implies: a Hong Kong annual report carries no Risk Factors and no Competition section, and the only place game licensing appears is the Structure Contracts disclosure, where Circular 13 (2009) is discussed as a foreign-ownership question - PRC legal advisers say the arrangement does not violate existing law, while warning of 'substantial uncertainties regarding the interpretation and application' of it. So the disclosed regulatory exposure is structural (VIE legality) rather than an operating constraint on game approvals; the filing simply does not speak to approval throughput at all, and any moat claim resting on it would be unsourced. | SK hynix's durable advantage rests on an HBM process-and-packaging lead: it held roughly 62% of the HBM market in Q2 2025 (Counterpoint) as NVIDIA's key HBM partner, and delivered industry-first HBM4 mass production. That lead drove record FY2025 results with a 49% operating margin, though rivals are qualifying competing HBM parts. | Moderna's 10-K rests its competitive case on the mRNA platform and the IP wrapped around it: the company states it believes its capabilities "across mRNA technology, drug discovery, development and manufacturing" differentiate it, and reports more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed abroad, 485 pending applications, and granted patents on Spikevax, mNEXSPIKE and mRESVIA projected to expire in 2041 (U.S.) and 2036 (Europe), plus trade secrets and manufacturing know-how it calls substantial. The filing is equally direct about the limits: the principal COVID rival's vaccine "is also based on mRNA technology"; a competitor's European Commission contract keeps Moderna out of many European COVID markets until year-end 2026; RSV sales are "minimal to date" behind Pfizer and GSK; and the risk factors warn that "the mRNA medicines field is growing rapidly, with increased competitive pressure from large and more established pharmaceutical companies." What is durable is science and plant rather than commercial position: Moderna bought and operates the Norwood (MTC) campus, completed a Marlborough site purpose-built for intismeran autogene that began shipping patient batches in September 2025, and runs UK, Canada and Australia facilities that were fully licensed in 2025, each government having entered a multi-year commitment to purchase mRNA products from the company. |
| Chain position | Both a downstream AI deployer and an upstream supplier: the report says Tencent Cloud 'achieved profit at scale due to increased enterprise demand for AI workloads' while AI is also credited with improving its own ad targeting and game content production. | Primary supplier of HBM (high-bandwidth memory) stacked onto NVIDIA's AI accelerators; HBM represented roughly 77% of Q2 2025 revenue. | A vertically integrated mRNA developer-manufacturer that sits between upstream licensors and government or retail buyers: it in-licenses the Penn modified-mRNA patents non-exclusively through Cellscript and mRNA RiboTherapeutics at low-single-digit royalties and NIAID's prefusion coronavirus spike and prefusion RSV F patents, manufactures drug substance at the owned Norwood MTC campus and individualized therapy at Marlborough, runs Moderna-built plants in the UK, Canada and Australia against multi-year government purchase commitments, and relies on CMOs for critical raw material production and fill-finish. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.42 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.24 at weight 0.20 · swarm bullish Editorial prior, not backtested. | +0.05 at weight 0.20 · swarm bearish Editorial prior, not backtested. |